

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-29. (Cancelled).

30. (Previously Presented) A mutant antibody that comprises a mutant immunoglobulin chain, the mutant antibody having higher affinity for an antigen than a parent antibody that comprises a parent immunoglobulin chain, wherein the mutant immunoglobulin chain comprises an amino acid substitution that eliminates a variable region glycosylation site of the parent immunoglobulin chain, said elimination having the effect of increasing the affinity of the mutant antibody relative to the parent antibody.

31. (Previously Presented) The mutant antibody of claim 30, wherein the glycosylation site is an N-linked glycosylation site selected from the group consisting of:

(1) -Asn-X-Ser-; and

(2) -Asn-X-Thr-;

wherein X is an amino acid other than Pro.

32. (Previously Presented) The mutant antibody of claim 30, wherein the glycosylation site is an O-linked glycosylation site selected from the group consisting of:

(1) -Thr-X-X-Pro-; and

(2) —Ser-X-X-Pro-;

wherein X is an amino acid.

33. (Previously Presented) The mutant antibody of claim 30, wherein the mutant antibody is a humanized version of the parent antibody.

34. (Previously Presented) The mutant antibody of claim 30, whose variable region has no glycosylation sites.

35. (Previously Presented) The mutant antibody of claim 30, whose variable region has no N-linked glycosylation sites.

36. (Previously Presented) The mutant antibody of claim 30, wherein the parent antibody is murine M195 antibody.

37. (Previously Presented) The mutant antibody of claim 30, wherein the mutant antibody is a humanized M195 antibody.

38. (Previously Presented) The mutant antibody of claim 30, wherein the antigen is a cell surface glycoprotein.

39. (Previously Presented) The mutant antibody of claim 30, wherein the mutant immunoglobulin chain is an immunoglobulin heavy chain.

40. (Previously Presented) The mutant antibody of claim 30, wherein the amino acid substitution is a conservative amino acid substitution.

41. (Previously Presented) The mutant antibody of claim 31, wherein the mutant immunoglobulin chain is an immunoglobulin heavy chain.

42. (Previously Presented) The mutant antibody of claim 31, wherein the amino acid substitution is a conservative amino acid substitution.

43. (Previously Presented) The mutant antibody of claim 32, wherein the mutant immunoglobulin chain is an immunoglobulin heavy chain.

44. (Previously Presented) The mutant antibody of claim 32, wherein the amino acid substitution is a conservative amino acid substitution.

45. (Previously Presented) The mutant antibody of claim 38, wherein the cell surface glycoprotein is the CD33 antigen.

46 (new) The mutant antibody of claim 30, wherein the mutation is in a complementary determining region of the parent immunoglobulin chain and the parent antibody binds an epitope of the antigen consisting of polypeptide.

47. (new) A method for producing a mutant antibody having higher affinity for an antigen relative to a parent antibody, the method comprising

introducing a mutation into a polynucleotide sequence encoding a chain of the parent antibody, whereby the polynucleotide encodes a mutant immunoglobulin chain comprising an amino acid substitution that eliminates a variable region glycosylation site of the parent immunoglobulin chain,

expressing said mutant sequence in a cell; and

determining that said elimination has the effect of increasing the affinity of the mutant antibody relative to the parent antibody.

48. (new) The method of claim 47, wherein the amino acid substitution is a conservative amino acid substitution.

49. (new) The method of claim 47, wherein the mutation is in a complementary determining region of the parent immunoglobulin chain and the parent antibody binds an epitope of the antigen consisting of polypeptide.